Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (DTC) after total thyroidectomy for remnant ablation, adjuvant treatment or treatment of persistent disease. 131I retention data, which are used to indicate the time at which a 131I treated DTC patient can be released from the hospital, may bring some insights regarding clinical factors that prolong the length of hospitalization. The aim of this study was to investigate the 131I whole-body retention in DTC patients during 131I therapy. Methods: We monitored 166 DTC patients to follow the 131I whole-body retention during 131I therapy with a radioactivity detector fixed on the ceiling of each protected room. A linear regression fit permitted us to estimate the whole-body 131I effective half-life in each patient, and a relationship was sought between patients’ clinical characteristics and whole-body effective 131I half-life. Results: The effective 131I half-life ranged from 4.08 to 56.4 h. At multivariable analysis, longer effective 131I half-life was related to older age and extensive extra-thyroid disease. Conclusions: 131I effective half-life during 131I treatment in DTC patients is highly variable among patients and is significantly longer in older and in patients with RAI uptake in large thyroid remnants or in extrathyroidal disease that significantly prolongs the whole-body retention of 131I.

Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer / Klain, Michele; Nappi, Carmela; De Risi, Marina; Piscopo, Leandra; Volpe, Fabio; Manganelli, Mariarosaria; Caiazzo, Elisa; Bianco, Davide; Schlumberger, Martin; Cuocolo, Alberto. - In: DIAGNOSTICS. - ISSN 2075-4418. - 11:10(2021), pp. 1740-1748. [10.3390/diagnostics11101740]

Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer

Klain, Michele;Nappi, Carmela;De Risi, Marina;Piscopo, Leandra;Volpe, Fabio;Manganelli, Mariarosaria;Caiazzo, Elisa;Bianco, Davide;Cuocolo, Alberto
2021

Abstract

Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (DTC) after total thyroidectomy for remnant ablation, adjuvant treatment or treatment of persistent disease. 131I retention data, which are used to indicate the time at which a 131I treated DTC patient can be released from the hospital, may bring some insights regarding clinical factors that prolong the length of hospitalization. The aim of this study was to investigate the 131I whole-body retention in DTC patients during 131I therapy. Methods: We monitored 166 DTC patients to follow the 131I whole-body retention during 131I therapy with a radioactivity detector fixed on the ceiling of each protected room. A linear regression fit permitted us to estimate the whole-body 131I effective half-life in each patient, and a relationship was sought between patients’ clinical characteristics and whole-body effective 131I half-life. Results: The effective 131I half-life ranged from 4.08 to 56.4 h. At multivariable analysis, longer effective 131I half-life was related to older age and extensive extra-thyroid disease. Conclusions: 131I effective half-life during 131I treatment in DTC patients is highly variable among patients and is significantly longer in older and in patients with RAI uptake in large thyroid remnants or in extrathyroidal disease that significantly prolongs the whole-body retention of 131I.
2021
Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer / Klain, Michele; Nappi, Carmela; De Risi, Marina; Piscopo, Leandra; Volpe, Fabio; Manganelli, Mariarosaria; Caiazzo, Elisa; Bianco, Davide; Schlumberger, Martin; Cuocolo, Alberto. - In: DIAGNOSTICS. - ISSN 2075-4418. - 11:10(2021), pp. 1740-1748. [10.3390/diagnostics11101740]
File in questo prodotto:
File Dimensione Formato  
Klain et al. Diagnostics (2021).pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 1.51 MB
Formato Adobe PDF
1.51 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/858058
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact